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Introduction
• Melanoma is the rarest yet most
aggressive of the common forms of skin
cancer
• Melanoma brain metastases (MBMs) are
a leading cause of morbidity and mortality
for patients with advanced melanoma
• Previous studies have implicated
oxidative phosphorylation (OXPHOS) in
the pathogenesis of MBM and in
suppression of the anti-tumor immune
response
• Clinically, MBMs with high OXPHOS had
decreased sensitivity to immunotherapy
and targeted gene therapy
• However, the role of OXPHOS in
modulating tumor immunity in MBM
remains unclear
Hypothesis
We hypothesize that OXPHOS suppresses
the immuneresponse in MBMs.
Methods and Materials
Fluorescence Tagging: D4M murine
melanoma cells were cultured and stably
transfected with lentiviral particles co-
expressing firefly luciferase and RFP, and
blasticidin antibiotic resistance (GenTarget)
Selection: D4M sensitivity to blasticidin
(Bsd) treatment (0.1 μg/mL – 1000 μg/mL)
was evaluated by Cell Titer Blue (CTB)
assay. Transfected D4M cells underwent
dual-selection with blasticidin antibiotic
treatment (100 μg/mL) and FACS
Drug Treatments: Cells were treated with
complete media, DMSO, and 0.1 - 5 μM of
IPN-60090 (glutaminase inhibitor) and
IACS-010759 (mitochondria complex I
inhibitor).
Cellular Metabolism Analysis: The
MitoStress Test was run on Seahorse 96-
well XF Analyzer to measure oxygen
consumption rate (OCR) of D4M cells 24h
post-drug treatment
Cytokine Analysis: Cell media supernatant
was collected at 24h post-treatment with 1
μM IACS-010759. Cytokine array analysis
was performed using the Mesoscale U-
PLEX platform to assess the effect of
OXPHOS inhibition on D4M melanoma
secretion of cytokines and chemokines
involved in immune system regulation
Conclusions
• IACS-010759 and IPN-60090 significantly
inhibited OXPHOS levels in D4M cells
• Treatment with OXPHOS inhibitors
increased the level of certain immune
activators and decreased levels of pro-
tumor cytokines secreted by D4M cells
• D4M is more sensitive to inhibition of
Complex I than glutaminase inhibition.
• Our results are consistent with growing
data showing mitochondrial metabolism
and OXPHOS has diverse and critical
functions in cancer immune evasion.
• We plan to further assess the long-term
effects of OXPHOS inhibition on D4M
cytokine expression
• Future studies will examine the impact of
the tumor microenvironment in MBM and
how it influences the rate and sensitivity
of OXPHOS in melanoma cells through
co-culture with astrocytes and in animal
models of MBM. Animal studies will utilize
luciferase expression for in-vivo imaging
• Better understanding of cancer
metabolism and its effect on immune
response will allow for new, efficient
treatments combining metabolic inhibitors
with immune-checkpoint therapy.
Oxidative Phosphorylation (OXPHOS) Modulation of 
Immune Response in Melanoma
Alice S. Liu1,2, Renato A. Guerrieri, BS1,2, and Michael A. Davies, MD, PhD1,2,3
1Dept. of Melanoma Medical Oncology, 2Dept. of Translational Molecular Pathology, 3Dept. of Systems Biology, The 
University of Texas MD Anderson Cancer Center, Houston, TX
Aim
To better understand the role of OXPHOS in
MBM pathogenesis and immunosuppression,
we investigated the metabolic and
immunologic effects of pharmacological
OXPHOS inhibitors using IPN-60090 and






Figure 3: (A) Fluorescent microscopy images of D4M cells
before and after transfection and selection with blasticidin
and FACS. (B) Flow cytometry indicating increasing
percentage of RFP+ D4M cells.
Figure 2: D4M cell vitality 
after blasticidin antibiotic 
treatment analyzed by 
CTB Assay. Dots 
represent mean of 
replicates (n=4) and lines 
represent SEM. 
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Figure 1: Schematic showing the 
Luc-RFP-Bsd vector used and the 
process of tagging and selecting 
for RFP+ D4M cells  
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Results (continued)
Figure 5: OXHPOS inhibition: (A) Increased expression of
anti-tumorigenic GM-CSF (p<0.0001) and CXCL10
(p=0.0144), (B) Decreased secretion of pro-tumorigenic CCL2
(p=0.0035), CXCL1 (p<0.0001), and CXCL2 (p=0.034), (C)





Immune Effect of 
IACS-010759 on D4M Cells
(A) Anti-tumorigenic Cyto-/Chemokines
(B) Pro-Tumorigenic Cyto-/Chemokines 
Figure 6: Schematic 
showing effect of IACS 







Figure 4: (A) Mitochondrial OXHPOS is represented by the
Oxygen Consumption Rate (OCR) of treated cells (n = 5).
(B) Treatment with 1 uM IACS-010759 and IPN-60090
decreased basal OCR by 86.6% (p<0.0001) and 18.2% (p =
0.056) respectively, and IACS decreased the maximum
OCR level by 66.8% (p<0.0001). Dots represent individual
replicates (n=3) and lines represent SEM.
(C) Other Cyto-/Chemokines 
OXPHOS Modules the Tumor 
Microenvironment
